ImmuPharma (LON:IMM) Stock Price Down 9.9% - Here's Why

Key Points

• ImmuPharma's share price dropped **9.9%** on Wednesday, trading at GBX **10.90** ($0.15) after previously closing at GBX **12.10** ($0.16).
• The company reported a quarterly EPS of GBX **(0.38)** and has a market capitalization of **£54.47 million** with a PE ratio of **-1,224.72**.
• ImmuPharma specializes in developing peptide-based therapeutics, including its lead program **Lupuzor™**, aimed at treating autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price fell 9.9% on Wednesday . The company traded as low as GBX 10.58 ($0.14) and last traded at GBX 10.90 ($0.15). 14,800,078 shares were traded during trading, an increase of 72% from the average session volume of 8,597,301 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Trading Down 9.9%

The firm has a 50 day simple moving average of GBX 4.66 and a two-hundred day simple moving average of GBX 3.39. The company has a market capitalization of £54.47 million, a PE ratio of -1,224.72 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.